Investigation of ranibizumab for the treatment of persistent diabetic neovascularization as assessed by super wide-field angiography (optos).

Trial Profile

Investigation of ranibizumab for the treatment of persistent diabetic neovascularization as assessed by super wide-field angiography (optos).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Nov 2014

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Diabetic retinopathy
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Jul 2011 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
    • 01 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top